We are live on ! Find out more
DA

Dunvegan Associates Portfolio holdings

AUM $85.1M
1-Year Est. Return 2.3%
This Fund
S&P 500
This Quarter Est. Return
+0.15%
1 Year Est. Return
-2.3%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$111M
AUM Growth
-$9.07M
Cap. Flow
-$8.21M
Cap. Flow %
-7.43%
Top 10 Hldgs %
53.93%
Holding
203
New
11
Increased
10
Reduced
30
Closed
7

Top Buys

Rank Stock Value
1
IBM icon
IBM
IBM
+$131K
2
AMZN icon
Amazon
AMZN
+$95.1K
3
IP icon
International Paper
IP
+$74.9K
4
INCO icon
Columbia India Consumer ETF
INCO
+$27.5K
5
UI icon
Ubiquiti
UI
+$26.1K

Top Sells

Rank Stock Value
1
MON
Monsanto Co
MON
+$5.79M
2
MOS icon
The Mosaic Company
MOS
+$1.82M
3
IRL
NEW IRELAND FUND INC
IRL
+$161K
4
UGP icon
Ultrapar
UGP
+$147K
5
PII icon
Polaris
PII
+$111K

Sector Composition

Rank Sector Weight
1 Energy 26.94%
2 Miscellaneous 18.94%
3 Healthcare 14.74%
4 Financials 14.6%
5 Consumer Staples 10.55%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
LNG icon
1
Cheniere Energy
LNG
$58.3B
$10.4M 9.41%
130,008
-584
-0.4% -$44.5K
MA icon
2
Mastercard
MA
$521B
$9.53M 8.62%
128,893
-592
-0.5% -$45.1K
MKC icon
3
McCormick & Company Non-Voting
MKC
$14.9B
$6.51M 5.89%
194,588
-696
-0.4% -$24K
WPZ
4
DELISTED
Williams Partners L.P.
WPZ
$5.96M 5.39%
99,358
-574
-0.6% -$33.9K
V icon
5
Visa
V
$712B
$5.72M 5.18%
107,312
-252
-0.2% -$13.5K
GLD icon
6
SPDR Gold Trust
GLD
$149B
$5.36M 4.84%
46,082
-348
-0.7% -$42.9K
AGN
7
DELISTED
Allergan plc
AGN
$5.34M 4.83%
29,983
-165
-0.5% -$36.9K
NVS icon
8
Novartis
NVS
$292B
$4.44M 4.01%
52,590
-447
-0.8% -$36.2K
ENB icon
9
Enbridge
ENB
$110B
$3.5M 3.17%
73,163
+95
+0.1% +$4.69K
TRP icon
10
TC Energy
TRP
$64.4B
$2.88M 2.6%
55,871
LLY icon
11
Eli Lilly
LLY
$1.05T
$2.87M 2.59%
44,208
-73
-0.2% -$4.62K
AMLP icon
12
Alerian MLP ETF
AMLP
$13.4B
$2.67M 2.42%
27,882
-163
-0.6% -$15.4K
ACN icon
13
Accenture
ACN
$116B
$2.67M 2.42%
32,859
MMM icon
14
3M
MMM
$89.9B
$2.26M 2.04%
19,070
UPS icon
15
United Parcel Service
UPS
$89.6B
$2.25M 2.04%
22,919
-95
-0.4% -$9.44K
CLR
16
DELISTED
CONTINENTAL RESOURCES INC.
CLR
$2.24M 2.03%
33,702
-108
-0.3% -$8.05K
IBB icon
17
iShares Biotechnology ETF
IBB
$10.5B
$2.2M 1.99%
24,150
-84
-0.3% -$7.37K
TEF
18
DELISTED
Telefonica
TEF
$1.8M 1.62%
159,274
-908
-0.6% -$10.7K
SGF
19
DELISTED
Aberdeen Singapore Fund
SGF
$1.66M 1.5%
133,728
-2,510
-2% -$32.8K
NVO
20
Novo Nordisk
NVO
$202B
$1.65M 1.49%
69,236
+266
+0.4% +$6.12K
THD icon
21
iShares MSCI Thailand ETF
THD
$351M
$1.57M 1.42%
18,691
-148
-0.8% -$12.2K
EWI icon
22
iShares MSCI Italy ETF
EWI
$1.12B
$1.44M 1.3%
45,798
PHO icon
23
Invesco Water Resources ETF
PHO
$2.05B
$1.23M 1.11%
49,840
+371
+0.7% +$9.51K
ABEV icon
24
Ambev
ABEV
$44.1B
$1.19M 1.08%
182,090
-1,580
-0.9% -$11.1K
SE
25
DELISTED
Spectra Energy Corp Wi
SE
$1.11M 1%
28,256

Similar funds

Dunvegan Associates's Q3 2014 Portfolio in Review

As of Q3 2014, Dunvegan Associates held 203 positions worth $111M, down 7.6% from $120M the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Dunvegan Associates withdrew a net $8.21M in Q3 2014, closing 7 positions and reducing 30 holdings. Its most notable exit was Monsanto Co, an estimated $5.79M position sold in full.

By sector, the portfolio is most concentrated in Energy at 27% of assets, up from 25% a quarter earlier, followed by Miscellaneous and Healthcare.

Against the trend, Dunvegan Associates opened a new position in International Paper worth $74K.

  • Dunvegan Associates's largest Q3 2014 buy was International Paper: 1,626 shares worth $74K.
  • Dunvegan Associates added most to IBM in Q3 2014, an estimated $131K increase.
  • Dunvegan Associates's biggest Q3 2014 reduction was NEW IRELAND FUND INC, cutting an estimated $161K.
  • Dunvegan Associates fully exited Monsanto Co in Q3 2014, selling an estimated $5.79M.
  • Dunvegan Associates's ten largest holdings make up 54% of its $111M portfolio in Q3 2014.
  • Dunvegan Associates opened 11 new positions and closed 7 in Q3 2014.
  • Dunvegan Associates's portfolio value fell 7.6% quarter-over-quarter to $111M.

Based on Dunvegan Associates's 13F filing for Q3 2014, filed 28 Apr 2017.